Alembic Pharmaceuticals Ltd, engaged in development, manufacturing, and marketing of formulations and APIs with 3 R&D and 5 manufacturing facilities, posted robust earnings growth in Q2FY26.
Financial Highlights:
- Revenues increased 15.9% year-on-year to ₹1,910 crore from ₹1,648 crore, led by strong growth in US generics, ex‑US markets, and APIs.
- Total expenses rose 13.01% to ₹1,694 crore from ₹1,499 crore, growing slower than revenues and supporting operating leverage.
- Consolidated net profit grew 20.26% to ₹184 crore from ₹153 crore, with EBITDA up sharply and margins improving.
- Earnings per share improved 20.51% to ₹9.40 from ₹7.80.
Outlook:
Alembic Pharmaceuticals Ltd aims to sustain growth via new product launches in regulated markets, API capacity expansion, and continued investment in R&D to support a healthy pipeline.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
